The Global ALEX trial was the first one to compare two ALK-Is in treatment-naïve patients with ALK+ (centrally tested by VENTANA anti-ALK, D5F3 IHC assay) NSCLC [37]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.